基础胰岛素-话题@MedSci

#基础胰岛素#

29篇内容 | 1720人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1623072, encodeId=91e716230e2fc, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Obes Metab：口服降糖药控制不佳的T2DM患者：基础胰岛素治疗模式, objectType=article, longId=103442, objectId=9632103442b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9632103442b6, replyNumber=0, likeNumber=45, createdTime=2017-06-28, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9632103442b6, moduleTitle=Diabetes Obes Metab：口服降糖药控制不佳的T2DM患者：基础胰岛素治疗模式, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9632103442b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623071, encodeId=205216230e172, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=Diabetes Metab ：2型糖尿病基础胰岛素联合附加治疗是否获益更多？, objectType=article, longId=99118, objectId=fff199118a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fff199118a3, replyNumber=0, likeNumber=40, createdTime=2017-05-20, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fff199118a3, moduleTitle=Diabetes Metab ：2型糖尿病基础胰岛素联合附加治疗是否获益更多？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fff199118a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623070, encodeId=879916230e0e0, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=ADA 2016：中国很大基础胰岛素研究“ORBIT”强势来袭！, objectType=article, longId=70900, objectId=6428e09003f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6428e09003f, replyNumber=0, likeNumber=73, createdTime=2016-06-17, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6428e09003f, moduleTitle=ADA 2016：中国很大基础胰岛素研究“ORBIT”强势来袭！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6428e09003f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623069, encodeId=0eca162306962, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=来得时救星，赛诺菲新一代基础胰岛素Toujeo喜获FDA批准, objectType=article, longId=47490, objectId=64644e490b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=64644e490b0, replyNumber=0, likeNumber=68, createdTime=2015-03-01, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=64644e490b0, moduleTitle=来得时救星，赛诺菲新一代基础胰岛素Toujeo喜获FDA批准, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=64644e490b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623068, encodeId=cb9f1623068d1, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=礼来基础胰岛素peglispro III期研究疗效优于来得时（IMAGINE研究）, objectType=article, longId=34819, objectId=ffd13481911, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ffd13481911, replyNumber=0, likeNumber=63, createdTime=2014-05-17, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffd13481911, moduleTitle=礼来基础胰岛素peglispro III期研究疗效优于来得时（IMAGINE研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffd13481911)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623067, encodeId=222a162306e88, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=赛诺菲Lyxumia联合基础胰岛素显著改善血糖控制, objectType=article, longId=25021, objectId=4131250213f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4131250213f, replyNumber=0, likeNumber=71, createdTime=2013-09-28, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4131250213f, moduleTitle=赛诺菲Lyxumia联合基础胰岛素显著改善血糖控制, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4131250213f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623066, encodeId=961a1623066b8, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=ADA 2013：ORIGIN试验最终癌症转归数据公布基础胰岛素无关癌症风险, objectType=article, longId=20742, objectId=ef1a20e42c0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ef1a20e42c0, replyNumber=0, likeNumber=61, createdTime=2013-07-03, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ef1a20e42c0, moduleTitle=ADA 2013：ORIGIN试验最终癌症转归数据公布基础胰岛素无关癌症风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ef1a20e42c0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623065, encodeId=6ee4162306586, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=ADA：长效基础胰岛素制剂夜间低血糖发生率低, objectType=article, longId=20580, objectId=943520580a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=943520580a2, replyNumber=0, likeNumber=70, createdTime=2013-06-29, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=943520580a2, moduleTitle=ADA：长效基础胰岛素制剂夜间低血糖发生率低, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=943520580a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623064, encodeId=82eb1623064b1, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=预混胰岛素控制餐后血糖或优于基础胰岛素, objectType=article, longId=6160, objectId=b4456160f8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b4456160f8, replyNumber=0, likeNumber=71, createdTime=2012-05-18, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b4456160f8, moduleTitle=预混胰岛素控制餐后血糖或优于基础胰岛素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b4456160f8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1623063, encodeId=a7eb162306313, content=<a href='/topic/show?id=2eb542152f0' target=_blank style='color:#2F92EE;'>#基础胰岛素#</a>, objectTitle=欧委会批准BYETTA辅助基础胰岛素用于治疗2型糖尿病, objectType=article, longId=5398, objectId=ae02539881, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ae02539881, replyNumber=0, likeNumber=78, createdTime=2012-04-18, rootId=0, userName=liuyong2987, userId=51af20470990, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ae02539881, moduleTitle=欧委会批准BYETTA辅助基础胰岛素用于治疗2型糖尿病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ae02539881)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

基础胰岛素

2020-05-29

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Obes Metab：口服降糖药控制不佳的T2DM患者：基础胰岛素治疗模式

2017-06-28

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

Diabetes Metab ：2型糖尿病基础胰岛素联合附加治疗是否获益更多？

2017-05-20

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

ADA 2016：中国很大基础胰岛素研究“ORBIT”强势来袭！

2016-06-17

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

来得时救星，赛诺菲新一代基础胰岛素Toujeo喜获FDA批准

2015-03-01

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

礼来基础胰岛素peglispro III期研究疗效优于来得时（IMAGINE研究）

2014-05-17

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

赛诺菲Lyxumia联合基础胰岛素显著改善血糖控制

2013-09-28

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

ADA 2013：ORIGIN试验最终癌症转归数据公布基础胰岛素无关癌症风险

2013-07-03

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

ADA：长效基础胰岛素制剂夜间低血糖发生率低

2013-06-29

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

预混胰岛素控制餐后血糖或优于基础胰岛素

2012-05-18

liuyong2987 (审核中...)

前往app查看评论内容

#基础胰岛素#

欧委会批准BYETTA辅助基础胰岛素用于治疗2型糖尿病

2012-04-18

科室
- - 订阅+
  - 更多科室
工具
服务